Future of Red Biotechnology in China

Report edition: 2010 edition(1)
Finished time: Apr. 2010
Document type: PPE
Total pages : 178
Language version: English
Published by CCM

Single user license: USD 10,000
Corporate license: USD 25,000

All the prices on this website exclude VAT.

CCM_sample_Future of Red Biotechnology in China

Introduction
Main contents
List of tables
List of figures

Description:

Red biotechnology (RB) refers to the biotechnology applied in pharmaceutical production and it has become the most important part in biotechnology industry. About 60% of achievements in biotechnology in the world are applied in production of bio-pharmaceuticals. At present, RB products mainly include gene recombinant drugs, blood products, vaccines, diagnostic reagents, etc. What is the current production situation of different RB products in China?

Driven by its substantial environmental or economic benefits, China’s RB industry has witnessed fast development and has played an increasingly important role in Chinese economic growth. However, the overall development of China’s RB industry remains in growth stage, and still has an enormous gap compared with developed countries. What is the future trend of Chinese RB industry development? What are the relevant supporting policies on Chinese RB industry? What have been the popular cutting-edge technologies in China in recent years? Where are the investment opportunities and what is the investment mode in China?

What is covered in this report?

- Overview of China’s red biotechnology;

- Detailed analysis of each sub-categories of red biotechnologies in China: gene recombinant drugs, blood products, vaccines, diagnostic reagent, etc., in terms of market data, major players, technical suppliers, technologies or R&D situations;

- Future prospects of each category of red biotechnologies, with key influencing factors and commercial opportunities

- Profiles of major players and research institutes

- Related policies and regulations

What benefits will you get?

- Gain a clear understanding about the industry landscape and latest developments in R&D, production, technology advancement and future trends in China’s red biotechnology;

- Keep informed of the precise development situation of key RB products with basic data and latest info;

- Gain reasonable and constructive suggestions on market opportunities in China’s RB fields;

- Figure out, current trend and future growth prospect of red biotechnology in China;

- Know more about how innovative players and research groups are carrying out innovation, collaboration and achieving commercial success in China.

Main contents:

No.	Content	Page
	Executive summary	1
	Methodology & sources	3
I	Overview of red biotechnology in China	5
	Introduction to red biotechnology	5
	Role of red biotechnology in medicine industry	5
	Overview of red biotechnology development	6
II	Development environment of red biotechnology in China	9
II-1	Macro economic environment	9
II-2	Policy environment	11
II-3	Medicine industry development	13
II-4	Venture capital	14
III	Market segments of red biotechnology industry in China	16
III-1	Gene recombinant drugs	16
III-1.1	Erythropoietin（EPO）	16
III-1.2	Insulin	19
III-1.3	G-CSF	24
III-1.4	Rh-GH	25
III-1.5	Interferon	29
III-1.6	Anti-tumor monoclonal antibody	30
III-2	Blood products	36
III-3	Human vaccines	45
III-4	Diagnostic reagent	61
III-4.1	Diagnostic reagent history in China	62
III-4.2	Current production situation in China	63
III-4.3	Producers information of Chinese diagnostic reagent	64
III-4.3.1	Biochemical diagnostic reagent	65
III-4.3.2	Immunodiagnostic reagent	66
III-4.3.3	Molecular diagnostic reagent	67
III-4.3.3.1	PCR reagent	67
III-4.3.3.2	Biochips	68
III-4.4	Forecast	69
III-5	Other red biotechnology based drugs	70
III-5.1	Antibiotic	70
III-5.1.1	Current antibiotic production in China	70
III-5.1.2	Penicillin production technology	71
III-5.1.3	Waste treatment technology	73
III-6	Forecast on supply & demand to the next 5~10 years	74
III-6.1	Forecast on gene recombinant market during 2010~2020	74
III-6.1.1	Supply of gene recombinant drugs during 2000~2020	75
III-6.1.2	Demand for gene recombinant drugs during 2009~2020	77
III-6.1.3	Difference between demand and supply during 2009~2020	77
III-6.2	Forecast on blood product market during 2010~2020	78
III-6.2.1	Supply of blood products during 2005~2020	78
III-6.2.2	Demand for blood products during 2009~2020	79
III-6.2.3	Difference between demand and supply during 2009~2020	79
III-6.3	Forecast on human vaccine market during 2010~2020	79
III-6.3.1	Supply of human vaccines during 2005~2020	80
III-6.3.2	Demand for human vaccines during 2009~2020	81
III-6.3.3	Difference between demand and supply during 2009~2020	81
III-6.4	Forecast on diagnostic reagent market during 2010~2020	81
III-6.4.1	Supply of diagnostic reagents during 2005~2020	82
III-6.4.2	Demand for diagnostic reagents during 2009~2020	83
III-6.4.3	Difference between demand and supply during 2009~2020	83
IV	Cutting edge technology development in China	84
IV-1	Stem cell treatment	84
IV-2	Monoclonal antibody	85
IV-3	Diagnostic reagent	86
IV-4	Vaccine	87
V	Geographical distribution of China’s red biotechnology industry	89
V-1	Regional distribution	89
V-2	Introduction to RB industrial clusters	89
V-3	Overview of major RB industrial bases	90
V-3.1	Changsha Natioanl Biomedical Industrial Base	90
V-3.2	Zhangjiang National Biomedical Industrial Base	93
V-3.3	Zhongguancun National Biomedical Industrial Base	95
V-3.4	Shenzhen National Biological Industry Base	99
V-3.5	Changchun National Biological Industry Base	99
V-3.6	Guangzhou National Biological Industry Base	99
V-3.7	Shijiazhuang National Biological Industry Base	100
V-4	Forecast on national biological industry base in the next 5~10 years	100
VI	Analysis of main Chinese companies in red biotechnology	102
VI-1	Choice of main Chinese companies in red biotechnology industry	102
VI-2	Analysis on main Chinese companies in red biotechnology industry	104
VI-2.1	Company engaged in biotech drugs	104
	- Shanghai FOSUN Pharmaceutical (GROUP) Co., Ltd.	0
VI-2.2	Companies engaged in blood products	107
	- Shanghai RAAS Blood Products Co., Ltd.	0
	- Hualan Biological Engineering, Inc..	0
VI-2.3	Company engaged in vaccine	112
	- Beijing Tiantan Biological Products Co., Ltd.	0
VI-2.4	Company engaged in bio-engineering drugs	114
	- Beijing SL Pharmaceutical Co., Ltd.	0
VI-2.5	Company engaged in antibiotics	116
	- Shandong Lukang Pharmaceutical Co., Ltd.	0
VI-2.6	Company engaged in diagnostic reagents	118
	- Shanghai Kehua Bio-Engineering Co., Ltd.	0
VII	Main foreign involvement in China’s red biotechnology	123
VII-1	Foreign companies in China	123
VII-1.1	GlaxoSmithKline (China) Co., Ltd.	123
VII-1.2	Pfizer (China) Co., Ltd.	127
VII-1.3	Novartis (China) Co., Ltd.	128
VII-1.4	Sanofi Pasteur (China) Co., Ltd.	131
VII-2	Comparison of foreign companies and Chinese companies	134
VII-3	Forecast on foreign involvement in China in next 5~10 years	135
VII-3.1	Forecast on Novartis expansion in China	136
VII-3.2	Forecast on GSK expansion in China	137
VII-3.3	Forecast on Sanofi-aventis expansion in China	137
VIII	Analysis of investment in the next 5 years	139
VIII-1	Investment opportunities in biopharmaceutical industry	139
VIII-1.1	Solid foundation of bio-pharmaceutical investment	139
VIII-1.2	Investment hotspots in China	143
VIII-2	Risk analysis of the investment in China’s red biotechnology	146
VIII-2.1	Risk from international environment	146
VIII-2.2	Risk from domestic environment	146
VIII-2.3	Estimation of bio-pharmaceutical investment risk in the next 5 years	152
IX	Profiles of key players in China	155
IX-1	Companies	155
IX-1.1	Gene recombinant drugs	155
IX-1.2	Blood products	160
IX-1.3	Vaccine	164
IX-1.4	Diagnostic reagent	168
IX-2	Research institutes	172

successfully!

CheckOut

List of tables:

Table No.	Table Title
Table	II-1.1 Annual benchmark lending rate of RMB
Table	II-2 Relevant policies on bio-pharmaceutical industry in China, 2006-2009
Table	II-3.1 Medicine industry output value in China, 2004-2008, billion USD
Table	III-1.1.1 Market share of major EPO manufacturers, 2009
Table	III-1.2.1 Three generations of insulin
Table	III-1.2.2 Main rh-insulin manufacturers in China, 2009
Table	III-1.3.1 Output of some G-CSF manufacturers, 2008
Table	III-1.4.1 Market share of main rh-GH manufacturers in China, 2006-2008
Table	III-1.5.1 Top four interferon manufacturers in China, 2009
Table	III-1.5.2 Market share of main interferon manufacturers in China, 2006-2008
Table	III-1.6.1 List of imported anti-tumor monoclonal antibody drugs
Table	III-1.6.2 List of domestic anti-tumor monoclonal antibody drugs
Table	III-2.1 Some major human albumin manufacturers in China, 2010
Table	III-2.2 Human albumin output of major manufacturers in China, 2008-2009
Table	III-2.3 Human immunoglobulin for intravenous injection output of major manufacturers, 2009
Table	III-3.1 Vaccines belonging to National Immunization Program, 2010
Table	III-3.2 Average import and export prices of human vaccines, 2006-2009
Table	III-3.3 Production situation of H1N1 Influenza A Vaccine in China, 2010 (Unit: thousand doses)
Table	III-3.4 Monthly lot release volume of top 4 H1N1 Influenza A vaccine in China, Sep-Dec. 2009 (Unit: thousand doses)
Table	III-3.5 All Inactivated Split Influenza vaccine lot release in China, 2009
Table	III-3.6 Situation of domestic HBV lot release, 2007-2009 (unit: thousand doses)
Table	III-3.7 Major manufacturers’ HBV lot release situation, 2009 (unit: thousand doses)
Table	III-3.8 Lot release volume of some major human vaccines, 2007-2009
Table	III-4.1 Comparison of three main diagnostic reagents
Table	III-4.3.1 Major diagnostic reagent producers in China, 2008
Table	III-4.3.1.1 Top 3 producers of biochemical diagnostic reagents in China, 2008
Table	III-4.3.2.1 Some producers of immunodiagnostic reagent in China, 2008
Table	III-4.3.3.1.1 Major PCR reagent producers in China, 2008
Table	III-4.3.3.2.1 Some biochips producers in China, 2009
Table	III-6.1.1.1 Supply of four gene recombinant drugs in China, 2000-2020
Table	III-6.1.1.2 Supply of gene recombinant drugs in China, 2009-2020
Table	III-6.1.2.1 Demand for gene recombinant drugs in China, 2009-2020
Table	III-6.1.3.1 Demand & supply gap of gene recombinant drugs in China, 2009-2020
Table	III-6.2.1.1 Supply of blood products in China, 2005-2020
Table	III-6.2.2.1 Demand for blood products in China, 2009-2020
Table	III-6.2.3.1 Demand & supply gap of blood products in China, 2009-2020
Table	III-6.3.1.1 Supply of human vaccines in China, 2005-2020
Table	III-6.3.2.1 Demand for human vaccines in China, 2009-2020
Table	III-6.3.3.1 Demand & supply gap of human vaccines in China, 2009-2020
Table	III-6.4.1.1 Supply of diagnostic reagents in China, 2005-2020
Table	III-6.4.2.1 Demand for diagnostic reagents in China, 2009-2020
Table	III-6.4.3.1 Demand & supply gap of diagnostic agents in China, 2009-2020
Table	IV-3.1 Info about HIV diagnostic kit of different generation
Table	V-1.1 Top 10 RB industrial regions by output value in China, 2008
Table	V-1.2 Top 10 RB industry regions by profit, 2008
Table	V-2.1 Seven National Biomedical Industrial Bases
Table	V-3.1.1 Eight investment sectors of this Base
Table	V-3.1.2.1 Incentives provided by the Base
Table	V-3.1.2.2 High-quality research centers in the Base
Table	V-3.2.2.1 Professional organizations
Table	V-3.2.2.2 Venture Service Centre
Table	V-3.3.2.1 Platform of Bio-technology
Table	V-3.3.2.2 Animal base
Table	V-3.3.2.3 R&D support
Table	V-3.3.2.4 Main equipments and instruments in second-stage test workshop
Table	V-3.5.1 Research centers
Table	VI-1.1 Major listed bio-pharmaceutical companies and their achievements
Table	VI-2.1.1 Employee structure in Shanghai FOSUN
Table	VI-2.1.2 Business performance of Shanghai FOSUN by field and product, H1 2009
Table	VI-2.1.3 Business performance of Shanghai FOSUN in different regions, H1 2009
Table	VI-2.1.4 Financial indicators of Shanghai FOSUN, 2007- 2009
Table	VI-2.2.1 Main products of Shanghai RAAS
Table	VI-2.2.2 Employee structure of Shanghai RAAS
Table	VI-2.2.3 Business performance of Shanghai RAAS by field and product, H1 2009
Table	VI-2.2.4 Business performance of Shanghai RAAS in different regions, H1 2009
Table	VI-2.2.5 Financial indicators of Shanghai RAAS, 2007 - 2009
Table	VI-2.2.6 Employee structure of Hualan Biological
Table	VI-2.2.7 Business performance of Hualan Biological by field and product, H1 2009
Table	VI-2.2.8 Business performance of Hualan Biological in different regions, H1 2009
Table	VI-2.2.9 Financial indicators of Hualan Biological, 2007- 2009
Table	VI-2.3.1 Employee structure of Tiantan Biological
Table	VI-2.3.2 Business performance of Tiantan Biological by product, H1 2009
Table	VI-2.3.3 Business performance of Tiantan Biological, H1 2009
Table	VI-2.3.4 Financial indicators of Tiantan Biological, 2007- 2009
Table	VI-2.4.1 Employee structure of Beijing SL
Table	VI-2.4.2 Business performance of Beijing SL by field and product, H1 2009
Table	VI-2.4.3 Business performance of Beijing SL in different regions, H1 2009
Table	VI-2.4.4 Financial indicators of Beijing SL, 2007-2009
Table	VI-2.5.1 Employee structure of Shandong Lukang
Table	VI-2.5.2 Business performance of Shandong Lukang by product, H1 2009
Table	VI-2.5.3 Business performance of Shandong Lukang in different regions, H1 2009
Table	VI-2.5.4 Financial indicators of Shandong Lukang, 2007- 2009
Table	VI-2.6.1 R&D Events reflecting research capability of Shanghai Kehua, 2005~2009
Table	VI-2.6.2 Four major diagnostic reagents of Shanghai Kehua
Table	VI-2.6.3 Employee structure of Shanghai Kehua
Table	VI-2.6.4 Business performance of Shanghai Kehua by field and product, H1 2009
Table	VI-2.6.5 Business performance of Shanghai Kehua in different regions, H1 2009
Table	VI-2.6.6 Financial indicators of Shanghai Kehua, 2007-2009
Table	VII-1.1.2.1 Prescription medicines introduced by GSK China into China
Table	VII-1.1.2.2 Vaccines introduced by GSK China into China
Table	VII-1.1.2.3 OTC medicines marketed by GSK China in China
Table	VII-1.1.2.4 Healthcare products of GSK China in China
Table	VII-1.4.2.1 Bacterial diseases and viral diseases
Table	VII-2.1 Financial performance comparison of Chinese and overseas biopharmaceutical companies, 2008-2009
Table	VII-3.1.1 Industry sales and growth of Novartis, 2010~2015
Table	VII-3.2.1 Industry sales and growth of GSK, 2009
Table	VII-3.3.1 Sanofi-aventis industry sales and growth in 2008 and 2009
Table	VIII-1.1.1 Main bio-industry policies
Table	VIII-2.2.1 regulatory policies and main impacts
Table	VIII-2.2.2 Important regulatory policies about blood product industry
Table	VIII-2.2.3 Average R&D expenses of different era in the world
Table	VIII-2.2.4 Domestic higher education graduates of biochemical pharmaceutical major
Table	VIII-2.2.5 Employees of bio-chemical and bio-pharmaceutical enterprises
Table	VIII-2.3.1 Estimated values of investment risks and EVBIR

List of figures:

Figure No.	Figure Title
Figure	I.1 Output value of bio-pharmaceuticals in China, 2004-2009
Figure	I.2 Proportion of bio-pharmaceuticals in China’s medicine industry, 2009
Figure	I.3 RB industrial output value changes in the proportion of China’s GDP, 2004-2009
Figure	II-1.1 China’s GDP growth, 2004-2009
Figure	II-2.1 Per capita disposable income of urban residents in China, 2004-2009
Figure	II-3.1 Medicine industry output value in China, 2004-Nov.2009
Figure	II-4 Procedure of venture capital in bio-pharmaceutical industry
Figure	III-1.1.1 EPO market value in China, 1999-2009
Figure	III-1.1.2 Forecast on EPO market value, 2010-2014
Figure	III-1.2.1 Global l insulin market value structure, 2009
Figure	III-1.2.2 Insulin market value structure in China, 2009
Figure	III-1.2.3 Output of rh-insulin in China, 2007-2009
Figure	III-1.2.4 Number of global diabetes patients, 1985-2007
Figure	III-1.2.5 Number of diabetes patients in China, 1978-2007
Figure	III-1.2.6 Market value of insulin in China, 2005-2009
Figure	III-1.2.7 Insulin import and export under HS code 29371200 in China, 2006-2009
Figure	III-1.2.8 Insulin import and export under HS code 30043100 in China, 2006-2009
Figure	III-1.2.9 Forecast on insulin market value, 2010-2014
Figure	III-1.3.1 Procurement value of G-CSF of all Chinese hospitals, 2004-2008
Figure	III-1.4.1 Output of rh-GH in China, 2006-2009
Figure	III-1.4.1 Market value of rh-GH in China, 2004-2009
Figure	III-1.4.3 Forecast on rh-GH output, 2010-2014
Figure	III-1.4.4 Forecast on rh-GH market value, 2010-2014
Figure	III-1.6.1 Global market value of anti-tumor monoclonal antibody, 2000-2009
Figure	III-1.6.2 Proportion of bio-pharmaceuticals market value in drug market, 2001-2007
Figure	III-1.6.3 Proportion of anti-tumor monoclonal antibody market value in bio-pharmaceuticals market, 2007
Figure	III-1.6.4 Rituximab market value in China, 2003-2008
Figure	III-1.6.5 Trastuzumab market value in China, 2003-2008
Figure	III-2.1 Geographical distribution of blood product manufacturers in China, 2009
Figure	III-2.2 Output of human albumin in China, 2004-2009
Figure	III-2.3 Average yield of human albumin in China, 2004-2008
Figure	III-2.4 Number Changes in active human albumin producers, 2004-2009
Figure	III-2.5 Human albumin market value in China, 2005-2009
Figure	III-2.6 Lot release volume of imported human albumin, 2007-2009
Figure	III-2.7 Forecast on human albumin output, 2010-2014
Figure	III-2.8 Forecast on human albumin market value, 2010-2014
Figure	III-3.1 Import and export situation of Chinese human vaccines, 2006-2009
Figure	III-3.2 Vaccines import volume shares of import origins, 2009
Figure	III-3.3 Market value of China’s vaccine industry, 2006-2009
Figure	III-3.4 Lot release volume of H1N1 Influenza A vaccine in China, 2009
Figure	III-3.5 Forecast on China’s H1N1 Influenza A vaccine output, 2010-2014
Figure	III-3.6 Situation of domestic Inactivated Split Influenza vaccine lot release, 2007-2009
Figure	III-3.7 Market capacity of Inactivated Split Influenza vaccine in China, 2007-2009
Figure	III-3.8 Proportion of homemade and imported seasonal influenza vaccine in China, 2009
Figure	III-3.9 Market share of seasonal influenza vaccine producers by volume in China, 2009
Figure	III-3.10 Lot release volume of imported seasonal influenza vaccine in China, 2007-2009
Figure	III-3.11 Forecast on China’s influenza vaccine market capacity, 2010-2014
Figure	III-3.12 Proportion of lot release volume of different HBV products, 2009
Figure	III-3.13 China’s HBV market capacity, 2007-2009
Figure	III-3.14 Lot release volume of imported HBV in China, 2007-2009
Figure	III-3.15 Forecast on HBV market capacity in China, 2010-2014
Figure	III-4.2.1 Output value of RB industry and diagnostic reagents industry in China, 2005- 2009
Figure	III-4.2.2 Share of different diagnostic reagents in China by output value, 2008
Figure	III-4.4.1 Forecast on output value of diagnostic reagent in China, 2010-2015
Figure	III-5.1.1.1 Output of four products in antibiotic industry in China, 2005-2009
Figure	III-5.1.2.1 Major procedures of three steps fermentation technology for penicillin production
Figure	III-5.1.3.1 Waste treatment procedure in Chinese antibiotic industry
Figure	IV-1.1 Major procedure of diabetes treatment with stem cell
Figure	IV-2.1 Major procedure of monoclonal antibody production
Figure	IV-4.1 Major procedure of avian influenza vaccine production
Figure	VIII-1.1.1 Chinese population and growth rate, 2000-2009
Figure	VIII-1.1.2 Elderly population and its proportion, 2000-2009
Figure	VIII-1.1.3 Per capital income and growth rate in urban areas
Figure	VIII-1.1.4 Per capital income and growth rate in rural areas
Figure	VIII-2.2.1 Exchange rate of CNY against USD
Figure	VIII-2.2.2 Industrialization process of bio-pharmaceutical products

CCM Customized Service on Market Research

Do you want Import & Export Analysis, Financial Data, Cost Analysis, Supply Chain Research etc. ? We will customize the specific research for you, in case the services listed above does not meet your precise requirements. Our product and industry research in China’s agriculture, chemicals, food & ingredients and life science markets will comprehensively cover the business information, which is able to help you arrive at strategic and profitable business decisions.

Please directly contact econtact@cnchemicals.com to specify your Market Research Requirement

SAMPLE DOWNLOAD

In order to provide you with access to all the free content on this site, we would like you to tell us who you are.
Please enter the following - you will only have to do this once. Or if you already have an account, please sign in here.

* Name
* Your E-mail address
* Your phone number
Your company
* Your industry

Recommend Report

Need some help to find your information ?

Search Report

Recommend Newsletter

Related market data

Related product

Related research

Future of Red Biotechnology in China

Single user license: USD 10,000
Corporate license: USD 25,000

All the prices on this website exclude VAT.

Description:

Main contents:

List of tables:

List of figures:

CCM Customized Service on Market Research

SAMPLE DOWNLOAD

My Products (0 items)

Login/Register

Recommend Report

Need some help to find your information ?

Search Report

Recommend Newsletter

Related market data

Related product

Related research

Future of Red Biotechnology in China

Single user license: USD 10,000 Corporate license: USD 25,000 All the prices on this website exclude VAT.

Description:

Main contents:

List of tables:

List of figures:

CCM Customized Service on Market Research

SAMPLE DOWNLOAD

Single user license: USD 10,000
Corporate license: USD 25,000

All the prices on this website exclude VAT.